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Abstract
Background: There has been considerable effort to discover plant-derived antibacterials against methicillin-
resistant strains of Staphylococcus aureus (MRSA) which have developed resistance to most existing antibiotics,
including the last line of defence, vancomycin. Pentacyclic triterpenoid, a biologically diverse plant-derived natural
product, has been reported to show anti-staphylococcal activities. The objective of this study is to evaluate the
interaction between three pentacyclic triterpenoid and standard antibiotics (methicillin and vancomycin) against
reference strains of Staphylococcus aureus.
Methods and Results: The activity of the standard antibiotics and compounds on reference methicillin-sensitive
and resistant strains of S. aureus were determined using the macrodilution broth method. The minimum inhibitory
concentration (MIC) of the compounds was compared with that of the standard antibiotics. The interaction
between any two antimicrobial agents was estimated by calculating the fractional inhibitory concentration (FIC
index) of the combination. The various combinations of antibiotics and compounds reduced the MIC to a range of
0.05 to 50%.
Conclusion: Pentacyclic triterpenoids have shown anti-staphylococcal activities and although individually weaker
than common antibiotics produced from bacteria and fungi, synergistically these compounds may use different
mechanism of action or pathways to exert their antimicrobial effects, as implicated in the lowered MICs. Therefore,
the use of current antibiotics could be maintained in their combination with plant-derived antibacterial agents as a
therapeutic option in the treatment of S. aureus infections.
Background
The wide use of antibiotics in the treatment of bacterial
infections has led to the emergence and spread of resis-
tant strains. Staphylococcus aureus is an important
pathogen both in community acquired and healthcare
associated infections. The organism has successfully
evolved numerous strategies for resisting the action to
practically all antibiotics [1]. Resistance to methicillin is
now widely described in the community setting
(CMRSA), thus the development of new drugs or alter-
native therapies is urgently necessary.
Plants are known to produce a variety of compounds
to protect themselves against a range of microorganisms
including plant pathogens and environmental organisms,
an indication of the successful defense mechanisms
developed. Therefore, plants and their secondary meta-
bolites are a promising source to provide structurally
diverse bioactive compounds as potentially therapeutic
agents, including antimicrobials. However, plant-derived
antimicrobials are less potent. Hence, it becomes appar-
ent that plants adopt a different paradigm - synergy - to
combat infections [2]. Synergism has been defined as a
phenomenon in which two different compounds are
combined to enhance their individual activity. If the
combination results in worsening effect, it is called
antagonism. Effect which is less than synergistic but not
antagonistic is termed as additive or indifference [3].
Antibacterial natural products can be classified
according to a general biogenetic source, such as terpe-
noids, alkaloids, flavonoids and simple phenols. One of
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penoids, which comprises different types of compounds
which may be divided into more important chemical
structure groups. The main groups of triterpenoids are
represented by tetracyclic and pentacyclic derivatives.
Pentacyclic triterpenoids are all based on a 30-carbon
skeleton comprising five six-membered rings (ursanes
and lanostanes) or four six-membered rings and one
five-membered ring (lupanes and hopanes) [4]. Penta-
cyclic triterpenoids a-amyrin, betulinic acid and betuli-
naldehyde, and other related triterpenes such as
imberbic acid, oleanolic acid (oleanic acid), ursolic acid,
ulsolic acid, rotundic acid and zeylasteral have been
reported to possess antimicrobial activity (Figure 1)
[5-9]. A preliminary study on the antimicrobial activity
of a-amyrin, betulinic acid and betulinaldehyde against
clinical isolates of MRSA and MSSA showed inhibition
at concentrations in the range of 8 to 32 μg/ml [10].
The aims of the present investigation were to assess
the antimicrobial activity of the pentacyclic triterpenoids
and compare them to the effect of antibiotics (methicil-
lin and vancomycin) on the growth of two reference
strains of S. aureus; and to evaluate the interaction of
the pentacyclic triterpenoids and antibiotics on these
strains.
Methods
Study compounds and standard antibiotics
The pentacyclic triterpenoids, namely a-amyrin, betuli-
nic acid and betulinaldehyde used in this study were
obtained from Sigma Aldrich (USA) and Advanced
Technology Co (Hong Kong). The antibiotics methicillin
and vancomycin in powder form were also obtained
from Sigma Aldrich (USA), each with a potency of 850
μg/mg and 1107 μg/mg, respectively.
Bacterial strains
The bacterial strains used were S. aureus ATCC 29213
and ATCC 43300, which represent methicillin-sensitive
and resistant strains, respectively. The bacterial strains
were cultured onto Nutrient Agar (NA) (BD Difco,
USA) and incubated at 37°C for 16 to 18 hours. Isolated
colonies were selected and inoculated into cation-
adjusted Mueller-Hinton broth (CAMHB) (BD Difco,
USA) to a turbidity comparable to that of 0.5 McFarland
standard, which is equivalent to a bacterial count of
approximately 10
6 cfu/ml.
Determination of minimum inhibitory concentration (MIC)
and minimum bactericidal concentration (MBC)
The three compounds were screened for antimicrobial
activity using the macrodilution method [11]. To
determine the minimum inhibitory concentrations
(MICs), the compounds were dissolved in methanol to
give a stock concentration of 10240 μg/ml while the
antibiotics were dissolved in ultrapure water to give
stock concentrations of 5120 μg/ml. All stock concen-
trations of compounds and antibiotics were filter-steri-
lized using 0.20 μm syringe filter. Twofold serial
dilutions of the antibiotics and compounds were made
with CAMHB to give concentrations ranging from 1 to
512 μg/ml. Five hundred microliter of 10
6 cfu/ml bac-
terial suspension was added to the sterile capped 13 ×
100 mm test tubes, giving an inoculum of 5 × 10
5 cfu/
ml. Another 500 μl of antibiotics or compounds or
combinations of antibiotics and compounds were
pipetted into the tubes. The control tube did not have
any antibiotics or test compounds, but contained the
test bacteria and the solvent used to dissolve the anti-
biotics and compounds. The solvent was shown not to
affect the growth of the bacteria during the experi-
ments. The tubes were then incubated at 37°C for 18
to 24 h. The lowest concentration of compound and
antibiotic showing no visible growth was recorded as
the minimum inhibitory concentration (MIC). Each
assay was carried out in triplicate.
From each tube which showed no visible growth, 0.1
ml was subcultured on Blood Agar (BA) (Isolab, Malay-
sia) to determine the minimum bactericidal inhibition
(MBC), which is defined as the lowest concentrations of
test compounds that reduced the inoculums by ≥ 99.9%.
The plates were then incubated at 37°C for 24 h, after
which the colonies were counted. The concentration
which has colony count of less than 10 was considered
as the MBC.
Determination of interaction between compounds and
antibiotics
Combinations of compounds and antibiotics were tested
by the checkerboard method against the two reference
strains of S. aureus, grown in CAMHB [12]. The con-
centrations of a-amyrin, betulinic acid and betulinalde-
hyde tested ranged from 0.25 to 64 μg/ml and for
methicillin and vancomycin from 0.25 to 8 μg/ml. The
combination for each reference strain was tested in tri-
plicates. The concentration of the individual compound
in the combination of pentacyclic triterpenoids and anti-
biotics in which the growth of organisms is completely
inhibited is taken as the MIC of the individual com-
pound in the combination. The fractional inhibitory
concentration was calculated as follows:
FIC of compound a (FICa)=M I Co fc o m p o u n da in
combination/MIC of compound a alone
FIC of compound b (FICb) = MIC of compound b in
combination/MIC of compound b alone
The sum of fractional inhibitory concentration (FICs)
indices of two compounds in the combination was cal-
culated as follows: FICa + FICb = FICs
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index of 0.5 or less, additivity as a FIC index of more
than 0.5 and less than 4, and antagonism as FIC index
of more than 4 [13,14].
Results and discussion
Antibacterial activity of pentacyclic tritepenoids and
antibiotics against reference strains of S. aureus
The preliminary study showed that the pentacyclic tri-
terpenoids showed weak antibacterial activity against the
reference strains of methicillin-resistant (ATCC 43300)
and methicillin-sensitive S. aureus (ATCC 29213). Their
MICs were in the range of 64 to 512 μg/ml, which is
higher than that of vancomycin and methicillin (Table
1). All three triterpenoids exhibited bacteriostatic effect
against the reference strains of S. aureus at the concen-
trations tested.
Antibacterial activity of pentacyclic triterpenoids in
combination with antibiotics
Based on the FIC calculations (Table 2), the combina-
tions of two compounds involving a-amyrin and betuli-
nic acid, showed synergistic effect with FIC index of 0.5
or less. Betulinaldehyde had synergistic effect only
Figure 1 Pentacyclic triterpenoids isolated and reported to possess antimicrobial activity.
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with methicillin.
The MIC for betulinic acid was reduced to 1/8× MIC
i nt h ep r e s e n c eo fa-amyrin compared to the com-
pound’s individual effect (see Tables 1 and 2). Synergy
was evident for betulinic acid in combination with
methicillin and vancomycin, as the MIC of the com-
pound in the combinations were reduced to 1/64× MIC
and 1/8× MIC, respectively. Betulinaldehyde did not
show synergistic effect in combinations with a-amyrin,
betulinic acid and vancomycin. However, in the pre-
sence of vancomycin, the MIC of betulinaldehyde was
reduced to 1/1024× MIC against reference strain of
MRSA and 1/256× MIC against reference strains of
MSSA. Similarly, a-amyrin and betulinaldehyde had a
significant effect on enhancing the antibacterial activity
of methicillin when tested against the reference strains
of MRSA and MSSA, respectively. The combination of
the three triterpenoids was also tested, but there was no
inhibition on the growth of the organisms at the con-
centrations tested.
Combined antibiotic therapy may produce synergistic
effects in the treatment of bacterial infection and has
been shown to delay the emergence of antimicrobial
resistance [15,16]. Previous in vitro studies have
reported synergistic effect of combinations of different
plant-derived pure compounds, such as baicalin, tellima-
grandin I and rugosin B, and known antibiotic b-lactams
against MRSA strains [13,17-19]. Epigallocatechin-gallate
(EGCg), a principal constituent of tea, exhibited syner-
gism with antibiotics by destroying b-lactamase activity
as well as acting on the peptidoglycan of the cell wall
[2]. Berberine, a hydrophobic alkaloid produced by ber-
berry plants, exhibits weak antibacterial properties
because of its efflux by multidrug resistance pumps
(MDR) in pathogens. When berberine is combined with
5’-methoxyhydnocarpin, also produced by berberry
plants, the combination is a potent antibacterial agent as
5’-methoxyhydnocarpin blocks the MDR pumps [20,21].
Synergistic effect between plant-derived compounds and
antibiotics enables the use of the respective antibiotics
when their effectiveness as single agents are reduced
[22]. However, none of the plant-derived compounds,
including triterpenoids have successfully been developed
for clinical use as antibacterials, probably due to the
preference to utilize combinatorial chemistry libraries as
a source of chemical diversity rather than natural pro-
ducts [23].
There are numerous reports in the literature on the
antibacterial activities of the pentacyclic triterpenoids
used in this study. Betulinic acid isolated from the leaves
of Vitex negundo exhibited antimicrobial activity against
Bacillus subtilis [24] and Staphylococcus epidermidis
(MIC of 128 μg/ml). In the same study, no activity was
found against the Gram negative bacteria Pseudomonas
aeruginosa and Escherichia coli. Amyrins isolated from
Diopsyros melanoxylon were found to exhibit antimicro-
bial activity against both Gram negative and Gram posi-
tive bacteria, including S. aureus (MIC of 90 μg/ml) [5].
a-amyrin obtained from Trichodesma amplexicaule
Roth. showed activity in both bacteria and fungi, includ-
ing S. aureus [25]. Betulinaldehyde isolated from Dios-
pyros rhodocalyx exhibited both antimalarial (IC50 of
6.25 μg/ml on Plasmodium falciparum) and antimyco-
bacterial activity (MIC of 25 μg/ml on Mycobacterium
tuberculosis H37Ra) [26]. In this study, all three penta-
cyclic triterpenoids exhibited antimicrobial activity
against the two reference strains of S. aureus,o n eo f
which was methicillin-sensitive and the other methicil-
lin-resistant. Of the three compounds tested, betulinal-
dehyde exhibited the lowest effect on S. aureus as seen
in the high MIC, compared to a-amyrin and betulinic
acid. As the structures of these compounds are very
similar, their partition coefficients will be similar. There-
fore, the differences in MIC, particularly that of betuli-
naldehyde could be possibly due to the differences in
the mechanism of actions of these compounds on S.
aureus at the cellular level.
Methicillin and vancomycin, agents of b-lactam and
glycopeptides classes, respectively, are inhibitors of
cell wall biosynthesis. b-lactams block enzymes
involved in the cell wall synthesis while glycopeptides
block the transglycosylation and transpeptidation
reaction necessary to add new subunits to the grow-
ing peptidoglycan chain [27]. As the structures of the
pentacyclic triterpenoids are different from both these
anti-staphylococcal agents, the pathways in the anti-
microbial activity of these compounds may have a
novel mechanism or target in S. aureus.T h et r i t e r p e -
noids in combination with methicillin or vancomycin
could act on different target sites of the bacteria that
could theoretically lead to either an additive or a
synergistic effect.
Table 1 Minimum inhibitory concentration (MIC) and
minimum bactericidal concentration (MBC) values of a-
amyrin, betulinic acid and betulinaldehyde on
Staphylococcus aureus strains
Compounds MIC (μg/ml) MBC (μg/ml)
ATCC
43300
*
ATCC
29213ǂ
ATCC
43300
*
ATCC
29213ǂ
a-amyrin 64 64 > 512 > 512
Betulinic acid 64 64 > 512 > 512
Betulinaldehyde 512 512 > 512 > 512
Vancomycin 4 2 64 32
Methicillin 16 2 > 512 32
* Reference methicillin-resistant S. aureus strain
ǂ Reference methicillin-sensitive S. aureus strain
Chung et al. Annals of Clinical Microbiology and Antimicrobials 2011, 10:25
http://www.ann-clinmicrob.com/content/10/1/25
Page 4 of 6However, the mechanism of action of triterpenoids is
not fully understood. It has been postulated that zeylast-
eral and demethylzeylasteral, triterpenoids which exhib-
ited antimicrobial activity against Gram-positive
bacteria, block cell division by inhibiting DNA synthesis
and macromolecular synthesis in Bacillus subtilis.T h e
inhibition of macromolecular synthesis could be due to
the damage to the cell membrane [6].
Conclusion
Synergism against the two reference strains was repro-
ducibly observed between the three compounds and cell
wall inhibitors of b-lactam and glycopeptide classes. The
best synergistic combination was betulinic acid and
methicillin.
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